Both SGLT-2 inhibitors and GLP-1 receptor agonists reduce cardiovascular risk (#MACE) in type 2 #diabetes mellitus, but they differ with respect to renal function. This may provide a more personalised approach to treatment.

https://pubmed.ncbi.nlm.nih.gov/37381019/ https://doi.org/10.1186/s12933-023-01877-6